Monthly Archives: July 2014
Mastering Brand Leadership To Reap Product Success
Last week’s post by Cameron Tew, “Why Great Brand Managers are Even Better Leaders,” was about how the best brand team leaders can elicit loyalty and focus from members who come to the product team from various functional teams. Ultimately,
Effectively & Efficiently Serving Thought Leaders
As this slide shows, Medical Affairs, Clinical Affairs and Marketing all have a hand in the management of Key Opinion Leaders (KOLs). Unfortunately, these functions are seldom bridged by processes, personnel or systems. When such work silos are created, you can be
SPECIAL: Highlights from 2014-2015 Digital Marketing Consortium 1st Roundtable
Best Practices, LLC recently held the first Roundtable for the 2014-2015 Digital Marketing Consortium. The virtual conference brought together digital marketing leaders from the pharmaceutical, medical device and biotech industries. The Roundtable, titled “Digital Marketing Service Delivery & Execution Excellence,”
Why Great Brand Managers are Even Better Leaders
Companies frequently search for ways to gauge success and often come up with practical measures to decide whether a product is a boon or a bust. Executives often believe that by setting measurable goals that brand teams can create a
Best Practices Kicks off 2014-2015 Medical Affairs Consortium
Medical Affairs functions have a significant influence on a healthcare company’s overall success. As the pharmaceutical, biotech, medical device, and health care technology markets become increasingly competitive and complex, it is crucial for leaders to understand how to best operate
Effective Thought Leader Engagement: Winning Support Vs. Earning Trust
For many years, my company has been asked by pharmaceutical and medical device companies how to best win the support of industry thought-leaders. As the health care environment has grown more complex and scrutinized, I no longer believe companies should
Success Factors & Lessons Learned in New Product Launches
In today’s competitive & crowded marketplace, biopharmaceutical companies are investing more and more resources to develop and launch new products for cardiovascular therapeutic areas. Consequently, recent industry product launches have produced both noteworthy failures and successes. It is now, more